NCT04509700: Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Sponsor: Incyte Corporation. Phase: PHASE2. Conditions: B-Cell Malignancies